12 Health Care Stocks Moving In Thursday's Pre-Market Session
Portfolio Pulse from Benzinga Insights
In Thursday's pre-market session, health care stocks showed significant movement. Yield10 Bioscience (YTEN) led the gainers with a 133.7% increase, while Tourmaline Bio (TRML) experienced the largest drop among the losers, decreasing by 33.4%. Other notable movements included Immunovant (IMVT) and argenx (ARGX) with substantial gains, and Apyx Medical (APYX) and Immatics (IMTX) among the notable losers. Several companies reported their Q4 earnings, influencing their stock prices.
March 21, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
argenx shares increased by 13.24% in pre-market trading, with a market cap of $23.9 billion.
The rise in argenx's stock price could be attributed to positive market reception or strategic company advancements.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Immunovant's stock rose 14.0% in pre-market trading, reaching a market cap of $5.2 billion.
Immunovant's stock increase suggests positive investor sentiment, possibly due to favorable company news or sector trends.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Yield10 Bioscience stock surged 133.7% in pre-market trading, with a market cap of $6.8 million.
The significant surge in YTEN's stock price indicates strong investor interest, potentially due to positive developments or expectations.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
Apyx Medical's stock declined 16.22% in pre-market trading to $1.55, following their Q4 earnings release.
The decline in APYX's stock price likely results from investor reactions to the Q4 earnings report, indicating potential concerns.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90
NEGATIVE IMPACT
Immatics shares declined by 15.49% in pre-market trading to $10.18, with a market cap of $1.0 billion.
The decrease in IMTX's stock price suggests negative investor sentiment, possibly due to recent company or industry developments.
CONFIDENCE 70
IMPORTANCE 75
RELEVANCE 80
NEGATIVE IMPACT
Tourmaline Bio shares fell 33.4% in pre-market trading, with a market cap of $762.9 million, following their Q4 earnings report.
The drop in TRML's stock price likely reflects investor disappointment or concerns following the Q4 earnings report.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100